Globus Medical, Inc. (NYSE:GMED – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve ...

Stifel重申买入评级和94.00美元的目标价，反映了对Globus Medical并购后指引和预期财务表现的审慎评估。该分析为投资者提供了一个框架，用于衡量这家医疗器械公司在未来几年实现每股收益增长目标所需的努力。凭借2.54的健康流动比率和适度的债务水平，GMED似乎已做好执行并购战略的准备。

Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

巴克莱：维持Globus Medical(GMED.US)评级，由增持调整至增持评级, 目标价由100.00美元调整至103.00美元。 Globus Medical（GMED.US）公司简介：Globus Medical Inc是 ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of ...

In this article, we are going to take a look at where Globus Medical, Inc. (NYSE:GMED) stands against the other medical technology stocks. The MedTech sector is crucial in healthcare, which ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Envestnet Portfolio Solutions Inc. lifted its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 3.0% ...